Biom’up finalizes U.S. commercial organization to support U.S. launch of HEMOBLASTTM Bellows

 On track with clinical, regulatory, financial, and commercial milestones
Saint-Priest, France, May 2, 2018 – 18.00 pm CEST – Biom’up (EPA: BUP), a specialist in surgical
hemostasis, today announced it has finalized the commercial infrastructure to support the imminent launch
of its lead product HEMOBLAST Bellows. The Company has recruited senior management and a large
number of independent specialist sales representatives to drive the nationwide marketing and sales
campaign of HEMOBLAST Bellows, which is expected to start in mid-2018.
Etienne Binant, Chief Executive Officer, said: “Under the leadership of Dave Clark, U.S. Vice President of
Sales, and Steven Ford, U.S. Vice President of Marketing, we have swiftly built a dedicated national hybrid
sales organization. With a large team of specialists now in place, and given its clinically demonstrated high
value, we are confident that HEMOBLAST Bellows will make substantial inroads and become a fixture of
hemostasis in operating rooms across the USA. Biom’up is now perfectly positioned to pursue its growth
ambitions and transition towards a fully-fledged commercial organization.”
The Company will use a hybrid sales model in the USA, relying on a team of veteran executives at Biom’up,
as well as a strong nationwide network of independent specialist sales representatives. This commercial
organization has already attracted in excess of 100 members, providing sufficient geographic coverage to
successfully launch HEMOBLAST Bellows later this year.
Biom’up’s own sales and marketing team, which will oversee the efforts of those in-direct sales
professionals, has recently been reinforced with the appointments of Clay Beaty as Area Vice President
Sales, Western U.S., Paul Uricchio as U.S. Director of Marketing, and Ken Mingus as Regional Business
Director, West Coast. Clay has over two decades of surgical device experience, including time focused in
sales and sales management within the hemostasis market (St Jude Medical, Baxter). Paul Uricchio has
extensive experience with launching hemostasis products (Mallinckrodt, The Medicines Company and
ZymoGenetics). Ken Mingus has a highly successful track record within the surgical device industry,
including key experience in the hemostasis market (Mallinckrodt, Baxter and Genzyme).
Biom’up obtained FDA approval for HEMOBLAST Bellows in December 2017. The expedited approval
arrived 7 months ahead of original plan, and led to an acceleration of the process of refocusing industrial
2
activities, as well as the recruitment of sales and marketing teams in the U.S. to prepare the mid-2018
commercial roll-out of our lead product in Europe and the U.S.
HEMOBLAST Bellows is an advanced hemostatic product to control bleeding in a broad range of surgical
procedures, such as cardiac surgery, general surgery, and orthopedic surgery. Biom’up conducted a
successful clinical trial in 258 patients admitted to cardio-thoracic, abdominal or orthopedic (lower limb)
surgeries, which met all of its primary and secondary endpoints. Given the compelling preliminary results
(93% effectiveness at 6 minutes, compared with 74% for the control arm), the Independent Data Monitoring
Committee (IDMC) unanimously recommended to stop the study after an interim analysis of the data, which
allowed us to accelerate the submission of our filing for premarket approval (PMA) to regulatory authorities.
Contacts
Biom’up
Chief Financial Officer
Jean-Yves Quentel
investisseurs@biomup.com
+33 4 86 57 36 10
NewCap
Investor relations
Tristan Roquet Montégon
biomup@newcap.eu
+33 1 44 71 00 16
LifeSci Advisors
Investors
Hans Herklots
hherklots@lifesciadvisors.com
+41 79 598 7149
About Biom’up
Founded in 2005 and based in Saint-Priest, close to Lyon (France), Biom’up develops hemostatic products
based on patented biopolymers that aim to simplify surgical procedures in numerous surgical specialties
(spine, cardiothoracic, general, orthopedic, plastic), and give patients a better quality of life. Its flagship
product, HEMOBLAST Bellows, is a unique hemostatic solution, ready to use (no preparation time needed,
no need to mix, no heat required), and usable once or several times during surgery. Developed by a worldrenowned
scientific team, HEMOBLAST Bellows has successfully met all primary and secondary endpoints
of a Phase III pivotal study involving 412 patients in the United States. HEMOBLAST Bellows obtained its
CE Mark in December 2016, and its PMA (Pre-Market Approval) application was granted by the U.S. Food
& Drug Administration in December 2017 with a view to commercializing in the United States in mid-2018.
Since inception, Biom’up has been supported by prominent European investors such as Bpifrance, Innobio,
GIMV, Lundbeckfond, Mérieux Participation, SHAM and ACG, as well as all the Company’s managers, who
have invested €2 million in equity. Biom’up successfully completed its IPO on Euronext Paris, raising €42.5
million in October 2017. In addition, the Company concluded a €16 million capital increase by means of a
public offering without preferential subscription rights in February 2018 and in April 2018, concluded a 25
million euro bond with Athyrium Opportunities III Acquisition LP, a US fund specializing in innovative
companies in the healthcare sector.
For more information, please visit www.biomup.com.
Forward looking statement
This press release may contain certain forward-looking statements. Although the Company believes its expectations
are based on reasonable assumptions, all statements other than statements of historical fact included in this press
release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control.
These statements may include, without limitation, any statements preceded by, followed by or including words such as
“target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,”
“should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking
statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the
Company’s actual results, performance or achievements to be materially different from the expected results,
performance or achievements expressed or implied by such forward-looking statements. Except as required by law,
the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons
actual results could differ materially from those anticipated in the forward-looking statements, even if new information
becomes available in the future. This press release has been prepared in both French and English. In the event of any
differences between the two texts, the French language version shall supersede.